{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:54:27Z","timestamp":1793040867598,"version":"4.5.0"},"reference-count":152,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>This review article explores the rapidly evolving field of bi-, tri-, and multi-specific NK cell engagers (NKCEs), highlighting their potential as a cutting-edge approach in cancer immunotherapy. NKCEs offer a significant advancement over conventional monoclonal antibodies (mAbs) by enhancing Antibody-Dependent Cellular Cytotoxicity (ADCC). They achieve this by stably and selectively binding to both NK cell activating receptors and tumor-associated antigens (TAAs). Unlike traditional mAbs, which depend on the relatively transient interaction between their Fc region and CD16a, NKCEs establish more robust connections with a range of activating receptors (e.g., CD16a, NKG2D, NKp30, NKp46, NKG2C) and inhibitory receptors (e.g., Siglec-7) on NK cells, thereby increasing cancer cell killing efficacy and specificity. This review article critically examines the strategies for engineering bi-, tri-, and multi-specific NKCEs for cancer immunotherapy, providing an in-depth analysis of the latest advancements in NKCE platform technologies currently under development by pharmaceutical and biotech companies and discussing the preclinical and clinical progress of these products. While NKCEs show great promise, the review underscores the need for continued research to optimize their therapeutic efficacy and to overcome obstacles related to NK cell functionality in cancer patients. Ultimately, this article presents an overview of the current landscape and future prospects of NKCE-based cancer immunotherapy, emphasizing its potential to revolutionize cancer treatment.<\/jats:p>","DOI":"10.3389\/fonc.2024.1483884","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:20:43Z","timestamp":1737505243000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Natural killer cell engagers for cancer immunotherapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Shahryar Khoshtinat","family":"Nikkhoi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Hatefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3389\/fimmu.2015.00368","article-title":"NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy","volume":"6","author":"Wang","year":"2015","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"crossref","first-page":"105997","DOI":"10.1016\/j.phrs.2021.105997","article-title":"Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment","volume":"175","author":"Lisi","year":"2022","journal-title":"Pharmacol Res"},{"key":"B3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41392-021-00868-x","article-title":"Emerging new therapeutic antibody derivatives for cancer treatment","volume":"7","author":"Jin","year":"2022","journal-title":"Signal Transduction Targeted Ther"},{"key":"B4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/antib9030034","article-title":"Monoclonal antibodies in cancer therapy","volume":"9","author":"Zahavi","year":"2020","journal-title":"Antibodies"},{"key":"B5","doi-asserted-by":"publisher","first-page":"100057","DOI":"10.1074\/jbc.REV120.013168","article-title":"Fc gamma receptor compositional heterogeneity: Considerations for immunotherapy development","volume":"296","author":"Barb","year":"2021","journal-title":"J Biol Chem"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020312","article-title":"Engineering anti-tumor monoclonal antibodies and fc receptors to enhance ADCC by human NK cells","volume":"13","author":"Dixon","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00410-0","article-title":"The role of IgG Fc receptors in antibody-dependent enhancement","volume":"20","author":"Bournazos","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.19.1.275","article-title":"IgG fc receptors","volume":"19","author":"Ravetch","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-380121","article-title":"Properties of mouse and human IgG receptors and their contribution to disease models","volume":"119","author":"Bruhns","year":"2012","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.913215","article-title":"From CD16a biology to antibody-dependent cell-mediated cytotoxicity improvement","volume":"13","author":"Coenon","year":"2022","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.21769\/BioProtoc.4285","article-title":"Evaluating human natural killer cells antibody-dependent cellular cytotoxicity (ADCC) using plate-bound anti-CD16 antibodies","volume":"12","author":"Liu","year":"2022","journal-title":"Bio Protoc"},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"B14","article-title":"Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc\u03b3RIIIa-158 V\/V and V\/F polymorphism","volume":"110","author":"Hatjiharissi","year":"2007","journal-title":"Blood J Am Soc Hematol"},{"key":"B15","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-009-0700-0","article-title":"Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing","volume":"58","author":"Kute","year":"2009","journal-title":"Cancer immunol Immunother"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.3892\/or.2014.3077","article-title":"Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS\/BRAF mutational status in colorectal cancer","volume":"31","author":"Seo","year":"2014","journal-title":"Oncol Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201712085","article-title":"Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells","volume":"217","author":"Srpan","year":"2018","journal-title":"J Cell Biol"},{"key":"B18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2021.08.007","article-title":"Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era","volume":"60","author":"Mand\u00f3","year":"2021","journal-title":"Breast"},{"key":"B19","article-title":"The application of the natural killer cells, macrophages and dendritic cells in treating various types of cancer","volume":"7","author":"Helmin-Basa","year":"2020","journal-title":"Phys Sci Rev"},{"key":"B20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jim.2016.12.002","article-title":"Characterization of FcgammaRIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells","volume":"441","author":"Hsieh","year":"2017","journal-title":"J Immunol Methods"},{"key":"B21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jim.2014.03.021","article-title":"Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies - impact of effector cells","volume":"407","author":"Chung","year":"2014","journal-title":"J Immunol Methods"},{"key":"B22","article-title":"A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell Malignancies","volume":"118","author":"Heider","year":"2011","journal-title":"Blood J Am Soc Hematol"},{"key":"B23","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/antib9040064","article-title":"Fc-engineering for modulated effector functions\u2014improving antibodies for cancer treatment","volume":"9","author":"Liu","year":"2020","journal-title":"Antibodies"},{"key":"B24","first-page":"1","article-title":"Boosting therapeutic potency of antibodies by taming Fc domain functions","volume":"51","author":"Kang","year":"2019","journal-title":"Exp Mol Med"},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.7932","article-title":"Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial","volume":"7","author":"Rugo","year":"2021","journal-title":"JAMA Oncol"},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-07-0696","article-title":"Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fc\u03b3 receptors","volume":"67","author":"Stavenhagen","year":"2007","journal-title":"Cancer Res"},{"key":"B27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.molimm.2022.10.005","article-title":"Margetuximab and trastuzumab deruxtecan: New generation of anti-HER2 immunotherapeutic agents for breast cancer","volume":"152","author":"Husna","year":"2022","journal-title":"Mol Immunol"},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-12-0692","article-title":"Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine productionBiKEs and triKEs enhance NK cell effector function","volume":"11","author":"Gleason","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"B29","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aba8564","article-title":"Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy","volume":"6","author":"Au","year":"2020","journal-title":"Sci Adv"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1039969","article-title":"Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy","volume":"13","author":"Nikkhoi","year":"2022","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(2001010)31:10<3121::aid-immu3121>3.0.co;2-4","article-title":"CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells","volume":"31","author":"Jacobs","year":"2001","journal-title":"Eur J Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2008.03027.x","article-title":"CD56bright natural killer (NK) cells: an important NK cell subset","volume":"126","author":"Poli","year":"2009","journal-title":"Immunology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.10.008","article-title":"The broad spectrum of human natural killer cell diversity","volume":"47","author":"Freud","year":"2017","journal-title":"Immunity"},{"key":"B34","doi-asserted-by":"crossref","DOI":"10.1038\/35018508","article-title":"The 3.2-\u00c5 crystal structure of the human IgG1 Fc fragment\u2013Fc\u03b3RIII complex","volume":"406","author":"Sondermann","year":"2000","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1706483114","article-title":"Transmembrane features governing Fc receptor CD16A assembly with CD16A signaling adaptor molecules","volume":"114","author":"Bl\u00e1zquez-Moreno","year":"2017","journal-title":"Proc Natl Acad Sci"},{"key":"B36","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.270.43.25762","article-title":"Ligand binding and phagocytosis by CD16 (Fc \u03b3 Receptor III) isoforms: PHAGOCYTIC SIGNALING BY ASSOCIATED \u03b6 AND \u03b3 SUBUNITS IN CHINESE HAMSTER OVARY CELLS (\u2217)","volume":"270","author":"Nagarajan","year":"1995","journal-title":"J Biol Chem"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1351","article-title":"Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion","volume":"107","author":"Bryceson","year":"2006","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-201632","article-title":"Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors","volume":"114","author":"Bryceson","year":"2009","journal-title":"Blood"},{"key":"B39","unstructured":"Tesar\n              M\n            \n            \n              Ellwanger\n              K\n            \n            \n              Fucek\n              I\n            \n            \n              Reusch\n              U\n            \n            \n              Ross\n              T\n            \n            \n              Koch\n              J\n            \n          \n          \n          2019"},{"key":"B40","doi-asserted-by":"crossref","DOI":"10.4161\/mabs.28591","article-title":"A novel tetravalent bispecific TandAb (CD30\/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells","volume":"6","author":"Reusch","year":"2014","journal-title":"MAbs"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0164","article-title":"Combining AFM13, a bispecific CD30\/CD16 antibody, with cytokine-activated blood and cord blood-derived NK cells facilitates CAR-like responses against CD30(+) Malignancies","volume":"27","author":"Kerbauy","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2095623","article-title":"AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial","volume":"63","author":"Sasse","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004701","article-title":"A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"136","author":"Bartlett","year":"2020","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"B46","article-title":"Innate cell engager (ICE\u00ae) AFM13 combined with preactivated and expanded (P+E) cord blood (CB)-derived natural killer (NK) cells for patients with refractory CD30-positive lymphomas: final results","volume":"142","author":"Yago Nieto","year":"2023","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1950264","article-title":"Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors","volume":"13","author":"Wingert","year":"2021","journal-title":"MAbs"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzx043","article-title":"Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells","volume":"30","author":"Gantke","year":"2017","journal-title":"Protein Eng Des Sel"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbt.2023.09.002","article-title":"Affibody-based hBCMA x CD16 dual engagers for NK cell-mediated killing of multiple myeloma cells","volume":"77","author":"Giang","year":"2023","journal-title":"N Biotechnol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1080\/19420862.2019.1616506","article-title":"Redirected optimized cell killing (ROCK(R)): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity","volume":"11","author":"Ellwanger","year":"2019","journal-title":"mAbs"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01478-w","article-title":"A BCMA\/CD16A bispecific innate cell engager for the treatment of multiple myeloma","volume":"36","author":"Kakiuchi-Kiyota","year":"2022","journal-title":"Leukemia"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202249947","article-title":"Therapeutic tactics for targeting B lymphocytes in autoimmunity and cancer","volume":"54","author":"Wemlinger","year":"2024","journal-title":"Eur J Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1208\/s12248-022-00744-8","article-title":"Nonclinical pharmacokinetics, pharmacodynamics, and translational model of RO7297089, A novel anti-BCMA\/CD16A bispecific tetravalent antibody for the treatment of multiple myeloma","volume":"24","author":"Cai","year":"2022","journal-title":"AAPS J"},{"key":"B54","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s44228-022-00023-5","article-title":"Phase I study of safety and pharmacokinetics of RO7297089, an anti-BCMA\/CD16a bispecific antibody, in patients with relapsed, refractory multiple myeloma","volume":"5","author":"Plesner","year":"2023","journal-title":"Clin Hematol Int"},{"key":"B55","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1182\/blood-2021-152463","article-title":"AFM28, a novel bispecific innate cell engager (ICE\u00ae), designed to selectively re-direct NK cell lysis to CD123+ Leukemic cells in acute myeloid leukemia and myelodysplastic syndrome","volume":"138","author":"G\u00f6tz","year":"2021","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2016.04.003","article-title":"Nanobodies as therapeutics: big opportunities for small antibodies","volume":"21","author":"Steeland","year":"2016","journal-title":"Drug Discovery Today"},{"key":"B57","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-3-030-74330-7_4","article-title":"Camelid single-domain antibodies for targeting cancer nanotheranostics","volume":"1","author":"Khaleghi","year":"2021","journal-title":"Cancer Nanotheranostics"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008295","article-title":"Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice","volume":"12","author":"Khoshtinat Nikkhoi","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B59","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.888838","article-title":"A generic strategy to generate bifunctional two-in-One antibodies by chicken immunization","volume":"13","author":"Harwardt","year":"2022","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4939-3684-7_28","article-title":"Generation of BiKEs and TriKEs to improve NK cell-mediated targeting of tumor cells","volume":"1441","author":"Felices","year":"2016","journal-title":"Natural Killer Cells"},{"key":"B61","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1182\/bloodadvances.2018029371","article-title":"Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL","volume":"3","author":"Felices","year":"2019","journal-title":"Blood advances"},{"key":"B62","article-title":"444 GTB-3550 tri-specific killer engager TriKE\u2122 drives NK cells expansion and cytotoxicity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients","volume":"9","author":"Felices","year":"2021","journal-title":"BMJ Specialist Journals"},{"key":"B63","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6066.CIR-19-0837","article-title":"Potent cytolytic activity and specific IL15 delivery in a second-generation trispecific killer engagerSecond-generation triKE potentiates NK-cell activity","volume":"8","author":"Felices","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00982-7","article-title":"New immune cell engagers for cancer immunotherapy","volume":"24","author":"Fenis","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00441","article-title":"NKG2D: A master regulator of immune cell responsiveness","volume":"9","author":"Wensveen","year":"2018","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00476","article-title":"NKG2D and its ligands: \u201cOne for all, all for one","volume":"9","author":"Zingoni","year":"2018","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00368","article-title":"Natural killer group 2, member D\/NKG2D ligands in hematopoietic cell transplantation","volume":"8","author":"Carapito","year":"2017","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/0471142735.im1109bs90","article-title":"Signal transduction during activation and inhibition of natural killer cells","author":"Watzl","year":"2010","journal-title":"Curr Protoc Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0649","article-title":"A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma","volume":"6","author":"Chan","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1854529","article-title":"Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response","volume":"10","author":"Raynaud","year":"2020","journal-title":"Oncoimmunology"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.4155\/tde-2022-0006","article-title":"Industry update: the latest developments in the field of therapeutic delivery, November 2021","volume":"13","author":"Timmins","year":"2022","journal-title":"Ther Deliv"},{"key":"B72","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","article-title":"Bi- and trispecific immune cell engagers for immunotherapy of hematological Malignancies","volume":"16","author":"Tapia-Galisteo","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16050877","article-title":"Preclinical characterization of the anti-leukemia activity of the CD33\/CD16a\/NKG2D immune-modulating triNKET((R)) CC-96191","volume":"16","author":"Lunn-Halbert","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1593\/neo.04316","article-title":"Downregulation and\/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma","volume":"6","author":"Raffaghello","year":"2004","journal-title":"Neoplasia"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02040","article-title":"NKG2D ligands-critical targets for cancer immune escape and therapy","volume":"9","author":"Schmiedel","year":"2018","journal-title":"Front Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00447","article-title":"NKG2D ligand shedding in response to stress: role of ADAM10","volume":"11","author":"Zingoni","year":"2020","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/nature01112","article-title":"Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation","volume":"419","author":"Groh","year":"2002","journal-title":"Nature"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2104991","article-title":"The MICA-NKG2D axis in clear cell renal cell carcinoma bolsters MICA as target in immuno-oncology","volume":"11","author":"Secchiari","year":"2022","journal-title":"Oncoimmunology"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1275904","article-title":"Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy","volume":"14","author":"Fantini","year":"2023","journal-title":"Front Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0098","article-title":"NKG2D receptor and its ligands in host defense","volume":"3","author":"Lanier","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.681615","article-title":"Circulating and tumor-infiltrating NK cells from clear cell renal cell carcinoma patients exhibit a predominantly inhibitory phenotype characterized by overexpression of CD85j, CD45, CD48 and PD-1","volume":"12","author":"Ziblat","year":"2021","journal-title":"Front Immunol"},{"key":"B82","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3389\/fimmu.2015.00573","article-title":"Activating KIRs and NKG2C in viral infections: toward NK cell memory","volume":"6","author":"Della Chiesa","year":"2015","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3389\/fimmu.2017.01317","article-title":"Elusive role of the CD94\/NKG2C NK cell receptor in the response to cytomegalovirus: novel experimental observations in a reporter cell system","volume":"8","author":"Pupuleku","year":"2017","journal-title":"Front Immunol"},{"key":"B84","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/eji.200324432","article-title":"The inhibitory NK cell receptor CD94\/NKG2A and the activating receptor CD94\/NKG2C bind the top of HLA-E through mostly shared but partly distinct sets of HLA-E residues","volume":"34","author":"Wada","year":"2004","journal-title":"Eur J Immunol"},{"key":"B85","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1074-7613(00)80574-9","article-title":"Association of DAP12 with activating CD94\/NKG2C NK cell receptors","volume":"8","author":"Lanier","year":"1998","journal-title":"Immunity"},{"key":"B86","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2021.06.018","article-title":"Anti-NKG2C\/IL-15\/anti-CD33 killer engager directs primary and iPSC-derived NKG2C+ NK cells to target myeloid leukemia","volume":"29","author":"Chiu","year":"2021","journal-title":"Mol Ther"},{"key":"B87","doi-asserted-by":"crossref","DOI":"10.1002\/(SICI)1521-4141(199905)29:05<1656::AID-IMMU1656>3.0.CO;2-1","article-title":"NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells","volume":"29","author":"Sivori","year":"1999","journal-title":"Eur J Immunol"},{"key":"B88","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0609692104","article-title":"Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46","volume":"104","author":"Walzer","year":"2007","journal-title":"Proc Natl Acad Sci"},{"key":"B89","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3389\/fimmu.2019.00909","article-title":"The natural cytotoxicity receptors in health and disease","volume":"10","author":"Barrow","year":"2019","journal-title":"Front Immunol"},{"key":"B90","doi-asserted-by":"crossref","DOI":"10.1084\/jem.186.7.1129","article-title":"p46, a novel natural killer cell\u2013specific surface molecule that mediates cell activation","volume":"186","author":"Sivori","year":"1997","journal-title":"J Exp Med"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.cell.2019.04.041","article-title":"Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity","volume":"177","author":"Gauthier","year":"2019","journal-title":"Cell"},{"key":"B92","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4593","article-title":"NKp46-specific single domain antibodies enable facile engineering of various potent NK cell engager formats","volume":"32","author":"Lipinski","year":"2023","journal-title":"Protein Sci"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100783","article-title":"Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant","volume":"3","author":"Demaria","year":"2022","journal-title":"Cell Rep Med"},{"key":"B94","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2022-170193","article-title":"Biological characterization and differential gene expression analysis of CYT-338 NK cell engager (NKE) against CD38 expressing tumors including multiple myeloma (MM)","volume":"140","author":"Lin","year":"2022","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3390\/cells12070996","article-title":"Derivation and preclinical characterization of CYT-303, a novel NKp46-NK cell engager targeting GPC3","volume":"12","author":"Arulanandam","year":"2023","journal-title":"Cells"},{"key":"B96","doi-asserted-by":"crossref","first-page":"S889","DOI":"10.1016\/j.annonc.2022.07.882","article-title":"756P Glypican-3 (GPC3) and NKp46 directed FLEX-NK engager antibody (CYT-303) recruits natural killer (NK) cells to tumors in a preclinical hepatocellular carcinoma (HCC) mouse model","volume":"33","author":"Arulanandam","year":"2022","journal-title":"Ann Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Am2022-3436","article-title":"Abstract 3436: Novel multifunctional tetravalent CD38 NKp46 FLEX NK engagers actively target and kill multiple myeloma cells","volume":"82","author":"Lin","year":"2022","journal-title":"Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01242","article-title":"Prognostic significance of tumor-infiltrating natural killer cells in solid tumors: A systematic review and meta-analysis","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1388018","article-title":"Interleukin-2 is required for NKp30-dependent NK cell cytotoxicity by preferentially regulating NKp30 expression","volume":"15","author":"Kim","year":"2024","journal-title":"Front Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2366","article-title":"Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors","volume":"17","author":"Delahaye","year":"2011","journal-title":"Nat Med"},{"key":"B101","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.2001004","article-title":"Affinity maturation of B7-H6 translates into enhanced NK Cell\u2013mediated tumor cell lysis and improved proinflammatory cytokine release of bispecific immunoligands via NKp30 engagement","volume":"206","author":"Pekar","year":"2021","journal-title":"J Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2100970","article-title":"Multifunctional NK cell-engaging antibodies targeting EGFR and NKp30 elicit efficient tumor cell killing and proinflammatory cytokine release","volume":"209","author":"Klausz","year":"2022","journal-title":"J Immunol"},{"key":"B103","doi-asserted-by":"crossref","first-page":"2315640","DOI":"10.1080\/19420862.2024.2315640","article-title":"Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers","volume":"16","author":"Boje","year":"2024","journal-title":"Mabs"},{"key":"B104","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1158\/2326-6066.CIR-21-0843","article-title":"Exploiting Natural Killer cell engagers to control pediatric B-cell precursor acute lymphoblastic leukemia","volume":"10","author":"Colomar-Carando","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B105","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.2100970","article-title":"Multifunctional NK cell\u2013engaging antibodies targeting EGFR and NKp30 elicit efficient tumor cell killing and proinflammatory cytokine release","volume":"209","author":"Klausz","year":"2022","journal-title":"J Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M403538200","article-title":"Negative regulation of T cell receptor signaling by Siglec-7 (p70\/AIRM) and Siglec-9","volume":"279","author":"Ikehara","year":"2004","journal-title":"J Biol Chem"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12455","article-title":"Siglec-7 defines a highly functional natural killer cell subset and inhibits cell-mediated activities","volume":"84","author":"Shao","year":"2016","journal-title":"Scand J Immunol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"8647","DOI":"10.1038\/s41598-020-64887-4","article-title":"Discovery of a new sialic acid binding region that regulates Siglec-7","volume":"10","author":"Yamakawa","year":"2020","journal-title":"Sci Rep"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2014.07.005","article-title":"Sweet escape: sialic acids in tumor immune evasion","volume":"1846","author":"Bull","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0728","article-title":"Sialic acids sweeten a tumor\u2019s life","volume":"74","author":"Bull","year":"2014","journal-title":"Cancer Res"},{"key":"B111","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adh4379","article-title":"Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers","volume":"9","author":"Bordoloi","year":"2023","journal-title":"Sci Adv"},{"key":"B112","doi-asserted-by":"crossref","first-page":"PR","DOI":"10.1158\/1538-7445.OVARIAN23-PR-006","article-title":"Abstract PR-006: A novel bispecific NK cell engager targeting FSHR and Siglec-7 displays potent anti-tumor immunity against ovarian cancer","volume":"84","author":"Bordoloi","year":"2024","journal-title":"Cancer Res"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6297","article-title":"Engineered antibodies of IgG1\/IgG3 mixed isotype with enhanced cytotoxic activities","volume":"68","author":"Natsume","year":"2008","journal-title":"Cancer Res"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.541813","article-title":"Dynamics of inter-heavy chain interactions in human immunoglobulin G (IgG) subclasses studied by kinetic Fab arm exchange","volume":"289","author":"Rispens","year":"2014","journal-title":"J Biol Chem"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2021.07.012","article-title":"BL-01, an Fc-bearing, tetravalent CD20 x CD5 bispecific antibody, redirects multiple immune cells to kill tumors in vitro and in vivo","volume":"24","author":"Interdonato","year":"2022","journal-title":"Cytotherapy"},{"key":"B116","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2016.1162932","article-title":"CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications","volume":"8","author":"Steinmetz","year":"2016","journal-title":"MAbs"},{"key":"B117","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1038\/s41467-024-46310-y","article-title":"Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma","volume":"15","author":"Grandclement","year":"2024","journal-title":"Nat Commun"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3390\/antib8040055","article-title":"Antibody structure and function: the basis for engineering therapeutics","volume":"8","author":"Chiu","year":"2019","journal-title":"Antibodies (Basel)"},{"key":"B119","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jim.2019.03.001","article-title":"A novel method for determining antibody-dependent cellular phagocytosis","volume":"468","author":"Kamen","year":"2019","journal-title":"J Immunol Methods"},{"key":"B120","article-title":"306 Evaluation of AB-101, an allogeneic cord blood-derived natural killer (NK) cell therapy, as an ADCC enhancer in hematologic and solid tumors","volume":"10","author":"Rogers","year":"2022","journal-title":"BMJ Specialist J"},{"key":"B121","first-page":"142","article-title":"AFM13 in combination with allogeneic natural killer cells (AB-101) in relapsed or refractory hodgkin lymphoma and CD30+Peripheral T-Cell lymphoma: a phase 2 study (LuminICE)","author":"Moskowitz","year":"2023","journal-title":"Blood"},{"key":"B122","article-title":"IPSC-derived NK cells exhibit potent in vitro and in vivo tumorcidal activity against patient-derived glioblastoma stem cells (GSCs)","volume":"69","author":"Ning","year":"2022","journal-title":"Neurosurgery"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03404-6","article-title":"Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy","volume":"146","author":"Huang","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1170042","article-title":"Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody","volume":"14","author":"Harwardt","year":"2023","journal-title":"Front Immunol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.669496","article-title":"Design of a trispecific checkpoint inhibitor and natural killer cell engager based on a 2 + 1 common light chain antibody architecture","volume":"12","author":"Bogen","year":"2021","journal-title":"Front Immunol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1062192","article-title":"A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells","volume":"7","author":"Piccione","year":"2015","journal-title":"MAbs"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2181016","article-title":"Strategies for clinical dose optimization of T cell-engaging therapies in oncology","volume":"15","author":"Ball","year":"2023","journal-title":"mAbs"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1961","article-title":"Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology","volume":"108","author":"Betts","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2012.11.027","article-title":"ADAM17 cleaves CD16b (FcgammaRIIIb) in human neutrophils","volume":"1833","author":"Wang","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2023.1611171","article-title":"Soluble B-cell maturation antigen as a monitoring marker for multiple myeloma","volume":"29","author":"Wiedemann","year":"2023","journal-title":"Pathol Oncol Res"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0324","article-title":"High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy","volume":"14","author":"Zhang","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B132","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.11.5512","article-title":"The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor","volume":"93","author":"Junghans","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxl110","article-title":"Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease","volume":"18","author":"Petkova","year":"2006","journal-title":"Int Immunol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00408","article-title":"The role of fcRn in antigen presentation","volume":"5","author":"Baker","year":"2014","journal-title":"Front Immunol"},{"key":"B136","article-title":"Role of local and systemic factors in increasing serum glycoprotein markers of pancreatic cancer","volume":"22","author":"Fabris","year":"1991","journal-title":"J Med"},{"key":"B137","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.838406","article-title":"Half-life extended nanobody-based CD38-specific bispecific killercell engagers induce killing of multiple myeloma cells","volume":"13","author":"Hambach","year":"2022","journal-title":"Front Immunol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01951","article-title":"The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies","volume":"11","author":"Vaisman-Mentesh","year":"2020","journal-title":"Front Immunol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2324836","article-title":"T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics","volume":"16","author":"Sun","year":"2024","journal-title":"MAbs"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.632687","article-title":"Immunogenicity risk profile of nanobodies","volume":"12","author":"Ackaert","year":"2021","journal-title":"Front Immunol"},{"key":"B141","doi-asserted-by":"crossref","DOI":"10.1093\/oxfordjournals.molbev.a004073","article-title":"Adaptive evolution of variable region genes encoding an unusual type of immunoglobulin in camelids","volume":"19","author":"Su","year":"2002","journal-title":"Mol Biol evolution"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.255679","article-title":"Phase I trial of (131)I-GMIB-anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients","volume":"62","author":"D\u2019Huyvetter","year":"2021","journal-title":"J Nucl Med"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M806889200","article-title":"General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold","volume":"284","author":"Vincke","year":"2009","journal-title":"J Biol Chem"},{"key":"B144","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/978-1-0716-2075-5_14","article-title":"Humanization of camelid single-domain a ntibodies","volume":"2446","author":"Sulea","year":"2022","journal-title":"Methods Mol Biol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1111\/febs.15809","article-title":"Immunogenicity and humanization of single-domain antibodies","volume":"289","author":"Rossotti","year":"2022","journal-title":"FEBS J"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1406040","article-title":"Preclinical immunogenicity risk assessment of biotherapeutics using CD4 T cell assays","volume":"15","author":"Walsh","year":"2024","journal-title":"Front Immunol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12943-020-01238-x","article-title":"Natural killer cells in cancer biology and therapy","volume":"19","author":"Wu","year":"2020","journal-title":"Mol Cancer"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15102712","article-title":"TIGIT Expression on Activated NK Cells Correlates with Greater Anti-Tumor Activity but Promotes Functional Decline upon Lung Cancer Exposure: Implications for Adoptive Cell Therapy and TIGIT-Targeted Therapies","volume":"15","author":"Hasan","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.6.3784","article-title":"TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells","volume":"181","author":"Trotta","year":"2008","journal-title":"J Immunol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191358","article-title":"Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models","volume":"13","author":"Otegbeye","year":"2018","journal-title":"PloS One"},{"key":"B151","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz4204","article-title":"Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses","volume":"6","author":"Chao","year":"2020","journal-title":"Sci Adv"},{"key":"B152","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s12032-023-01975-1","article-title":"Stem cell-assisted enzyme\/prodrug therapy makes drug-resistant ovarian cancer cells vulnerable to natural killer cells through upregulation of NKG2D ligands","volume":"40","author":"Li","year":"2023","journal-title":"Med Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1483884\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:21:08Z","timestamp":1737505268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1483884\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":152,"alternative-id":["10.3389\/fonc.2024.1483884"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1483884","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]},"article-number":"1483884"}}